Conclusions: A series of humanized anti-CEA M5A∆CH2 antibodies were designed for immunoPET imaging of colorectal cancer, and the [64Cu]Cu-DO3A-M5A∆CH2-C5 showed high tumor targeting and fast blood clearance supporting its potential for clinical trials. This evidence concerns the gene CEACAM5 and colorectal cancer.